NEW DELHI – “The pendulum is normalizing” in India’s embattled clinical trials sector, according to Suneela Thatte, president of the Indian Society for Clinical Research (ISCR). “We have been through a lot of negative publicity…but we have the worst period behind us,” Thatte told PharmAsia News in an interview.
India’s s nascent clinical research field and giant generic drugs sector have been under fire from health activists and international...